The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

GSK has penned another neuroscience pact, this time with Danish biotech Muna Therapeutics. | GSK has penned another ...

Once the companies are satisfied with the target, GSK will be in charge of taking the programs forward. It will lead drug ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big ...

GSK PLCGSK3.09%increase; green up pointing triangle extended its collaboration with Chongqing Zhifei Biological Products 300122-1.12%decrease; red down pointing triangle to commercialize its ...

But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term GSK plc (LON:GSK) shareholders for doubting their decision to hold, with the stock down 38 ...

Muna will take the lead in identifying and validating new Alzheimer’s targets, while GSK will be responsible for the ...